MT2013-31:Allo BMT for Metabolic Disorders, Osteopetrosis and Males With Rett Syndrome
Conditions:  Mucopolysaccharidosis I;  Mucopolysaccharidosis II;  Mucopolysaccharidosis VI;  Mucopolysaccharidosis VII;  Hurler Syndrome;  Hunter Syndrome;  Maroteaux Lamy Syndrome;  Sly Syndrome;  Glycoprotein Metabolic Disorders;  Alpha Mannosidosis;  Fucosidosis;  Aspartylglucosaminuria;  Adrenoleukodystrophy;  Peroxisomal Disorders;  Osteopetrosis;  Rett Syndrome;  Sphingolipidosis;  Gangliosidosis;  Globoid Cell Leukodystrophy;  Metachromatic Leukodystrophy;  Niemann Pick B;  Niemann Pick C Subtype 2;  I-cell DiseaseInterventions:  Procedure: blood stem cell transplant;  Drug: Rabbit Anti-Thymocyte Globulin (ATG);  Drug: Fludarabine;  Drug: Busulfan;  Drug: Cyclophosphamide;  Drug: Cyclosporine A (CSA);  Drug: Methylprednisolone;  Drug: Mycophenolate Mofetil (MMF);  Drug: Granulocyte-Colony Stimulating Factor (G-CSF);  Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);  Drug: N-acetylcysteine;  Drug: Celecoxib;  Drug: Vitamin E;  Drug: Alpha Lipoic AcidSponsor:  Masonic Cancer Center, University of MinnesotaRecruiting - verified July 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acetylcysteine | Cancer & Oncology | Celebrex | Leukodystrophies | Methylprednisolone | Research | Rett Syndrome | Transplants